THAR - NASDAQ
Tharimmune, Inc.
$3.38
+0.86%Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
At a Glance
Live Snapshotthar
Deferred Tax Liabilities (Non-Current)
Last Annual Value
117.93M
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
Tharimmune, Inc. Competitors Analysis of Deferred Tax Liabilities (Non-Current)
| Company | Deferred Tax Liabilities (Non-Current) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Tharimmune, Inc. NASDAQ:THAR | 117.93M | N/A | N/A | N/A |
Tharimmune, Inc. Fair Value Envelope
Related Guides
Continue your THAR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.